[1] C.J. Sigurdson, J.C. Bartz, M. Glatzel, Cellular and molecular mechanisms of prion
disease, Annu. Rev. Pathol. 14 (2019) 497–516.
[2] S.B. Prusiner, M.R. Scott, S.J. DeArmond, F.E. Cohen, Prion protein biology, Cell 93
(3) (1998) 337–348.
[3] M.W. Brazier, V. Lewis, G.D. Ciccotosto, G.M. Klug, V.A. Lawson, R. Cappai, J.
W. Ironside, C.L. Masters, A.F. Hill, A.R. White, S. Collins, Correlative studies
support lipid peroxidation is linked to PrP(res) propagation as an early primary
pathogenic event in prion disease, Brain Res. Bull. 68 (5) (2006) 346–354.
[4] J.A. Carroll, J.F. Striebel, B. Race, K. Phillips, B. Chesebro, Prion infection of mouse
brain reveals multiple new upregulated genes involved in neuroinflammation or
signal transduction, J. Virol. 89 (4) (2015) 2388–2404.
[5] C. Zhu, A. Aguzzi, Prion protein and prion disease at a glance, J. Cell Sci. 134 (17)
(2021).
[6] G.R. Mallucci, M.D. White, M. Farmer, A. Dickinson, H. Khatun, A.D. Powell,
S. Brandner, J.G. Jefferys, J. Collinge, Targeting cellular prion protein reverses
early cognitive deficits and neurophysiological dysfunction in prion-infected mice,
Neuron 53 (3) (2007) 325–335.
[7] A.K.K. Lakkaraju, K. Frontzek, E. Lemes, U. Herrmann, M. Losa, R. Marpakwar,
A. Aguzzi, Loss of PIKfyve drives the spongiform degeneration in prion diseases,
EMBO Mol. Med. 13 (9) (2021), e14714.
[8] J.A. Moreno, H. Radford, D. Peretti, J.R. Steinert, N. Verity, M.G. Martin,
M. Halliday, J. Morgan, D. Dinsdale, C.A. Ortori, D.A. Barrett, P. Tsaytler,
A. Bertolotti, A.E. Willis, M. Bushell, G.R. Mallucci, Sustained translational
repression by eIF2alpha-P mediates prion neurodegeneration, Nature 485 (7399)
(2012) 507–511.
[9] J.M. Bourgognon, J.G. Spiers, S.W. Robinson, H. Scheiblich, P. Glynn, C. Ortori, S.
J. Bradley, A.B. Tobin, J.R. Steinert, Inhibition of neuroinflammatory nitric oxide
signaling suppresses glycation and prevents neuronal dysfunction in mouse prion
disease, Proc. Natl. Acad. Sci. U. S. A. 118 (10) (2021).
[10] J. Schultz, A. Schwarz, S. Neidhold, M. Burwinkel, C. Riemer, D. Simon, M. Kopf,
M. Otto, M. Baier, Role of interleukin-1 in prion disease-associated astrocyte
activation, Am. J. Pathol. 165 (2) (2004) 671–678.
[11] M. Burwinkel, C. Riemer, A. Schwarz, J. Schultz, S. Neidhold, T. Bamme, M. Baier,
Role of cytokines and chemokines in prion infections of the central nervous system,
Int. J. Dev. Neurosci. 22 (7) (2004) 497–505.
[12] D. Hwang, I.Y. Lee, H. Yoo, N. Gehlenborg, J.H. Cho, B. Petritis, D. Baxter,
R. Pitstick, R. Young, D. Spicer, N.D. Price, J.G. Hohmann, S.J. Dearmond, G.
A. Carlson, L.E. Hood, A systems approach to prion disease, Mol. Syst. Biol. 5
(2009) 252.
[13] S. Sorce, M. Nuvolone, G. Russo, A. Chincisan, D. Heinzer, M. Avar, M. Pfammatter,
P. Schwarz, M. Delic, M. Muller, S. Hornemann, D. Sanoudou, C. Scheckel,
A. Aguzzi, Genome-wide transcriptomics identifies an early preclinical signature of
prion infection, PLoS Pathog. 16 (6) (2020), e1008653.
[14] J.M. Bourgognon, J.G. Spiers, H. Scheiblich, A. Antonov, S.J. Bradley, A.B. Tobin,
J.R. Steinert, Alterations in neuronal metabolism contribute to the pathogenesis of
prion disease, Cell Death Differ. 25 (8) (2018) 1408–1425.
[15] F. Klamt, F. Dal-Pizzol, M.L. Conte da Frota Jr., R. Walz, M.E. Andrades, E.G. da
Silva, R.R. Brentani, I. Izquierdo, J.C. Fonseca Moreira, Imbalance of antioxidant
defense in mice lacking cellular prion protein, Free Radic. Biol. Med. 30 (10)
(2001) 1137–1144.
[16] R. Gavin, N. Braun, O. Nicolas, B. Parra, J.M. Urena, A. Mingorance, E. Soriano, J.
M. Torres, A. Aguzzi, J.A. del Rio, PrP, 106-126) activates neuronal intracellular
kinases and Egr1 synthesis through activation of NADPH-oxidase independently of
PrPc, FEBS Lett. 579 (19) (2005) 4099–4106.
[17] Y.G. Park, J.K. Jeong, J.H. Lee, Y.J. Lee, J.W. Seol, S.J. Kim, T.Y. Hur, Y.H. Jung, S.
J. Kang, S.Y. Park, Lactoferrin protects against prion protein-induced cell death in
neuronal cells by preventing mitochondrial dysfunction, Int. J. Mol. Med. 31 (2)
(2013) 325–330.
[18] A.R. White, S.J. Collins, F. Maher, M.F. Jobling, L.R. Stewart, J.M. Thyer,
K. Beyreuther, C.L. Masters, R. Cappai, Prion protein-deficient neurons reveal
lower glutathione reductase activity and increased susceptibility to hydrogen
peroxide toxicity, Am. J. Pathol. 155 (5) (1999) 1723–1730.
[19] O. Milhavet, H.E. McMahon, W. Rachidi, N. Nishida, S. Katamine, A. Mange,
M. Arlotto, D. Casanova, J. Riondel, A. Favier, S. Lehmann, Prion infection impairs
the cellular response to oxidative stress, Proc. Natl. Acad. Sci. U. S. A. 97 (25)
(2000) 13937–13942.
[20] R. Faris, R.A. Moore, A. Ward, B. Race, D.W. Dorward, J.R. Hollister, E.R. Fischer,
S.A. Priola, Cellular prion protein is present in mitochondria of healthy mice, Sci.
Rep. 7 (2017), 41556.
[21] I.H. Flones, G. Ricken, S. Klotz, A. Lang, T. Strobel, C. Dolle, G.G. Kovacs,
C. Tzoulis, Mitochondrial respiratory chain deficiency correlates with the severity
of neuropathology in sporadic Creutzfeldt-Jakob disease, Acta Neuropathol
Commun 8 (1) (2020) 50.
[22] H.S. Choi, Y.G. Choi, H.Y. Shin, J.M. Oh, J.H. Park, J.I. Kim, R.I. Carp, E.K. Choi, Y.
S. Kim, Dysfunction of mitochondrial dynamics in the brains of scrapie-infected
mice, Biochem. Biophys. Res. Commun. 448 (2) (2014) 157–162.
[23] O. Andreoletti, E. Levavasseur, E. Uro-Coste, G. Tabouret, P. Sarradin, M.B. Delisle,
P. Berthon, R. Salvayre, F. Schelcher, A. Negre-Salvayre, Astrocytes accumulate 4-
hydroxynonenal adducts in murine scrapie and human Creutzfeldt-Jakob disease,
Neurobiol. Dis. 11 (3) (2002) 386–393.
[24] D.R. Brown, J. Sassoon, Copper-dependent functions for the prion protein, Mol.
Biotechnol. 22 (2) (2002) 165–178.
[25] M.W. Brazier, P. Davies, E. Player, F. Marken, J.H. Viles, D.R. Brown, Manganese
binding to the prion protein, J. Biol. Chem. 283 (19) (2008) 12831–12839.
[26] A. Singh, M.L. Mohan, A.O. Isaac, X. Luo, J. Petrak, D. Vyoral, N. Singh, Prion
protein modulates cellular iron uptake: a novel function with implications for prion
disease pathogenesis, PLoS One 4 (2) (2009) e4468.
[27] N.T. Watt, D.R. Taylor, T.L. Kerrigan, H.H. Griffiths, J.V. Rushworth, I.
J. Whitehouse, N.M. Hooper, Prion protein facilitates uptake of zinc into neuronal
cells, Nat. Commun. 3 (2012) 1134.
[28] B.S. Wong, T. Liu, R. Li, T. Pan, R.B. Petersen, M.A. Smith, P. Gambetti, G. Perry, J.
C. Manson, D.R. Brown, M.S. Sy, Increased levels of oxidative stress markers
detected in the brains of mice devoid of prion protein, J. Neurochem. 76 (2) (2001)
565–572.
[29] A.M. Thackray, R. Knight, S.J. Haswell, R. Bujdoso, D.R. Brown, Metal imbalance
and compromised antioxidant function are early changes in prion disease,
Biochem. J. 362 (Pt 1) (2002) 253–258.
[30] B.S. Wong, S.G. Chen, M. Colucci, Z. Xie, T. Pan, T. Liu, R. Li, P. Gambetti, M.S. Sy,
D.R. Brown, Aberrant metal binding by prion protein in human prion disease,
J. Neurochem. 78 (6) (2001) 1400–1408.
[31] M.W. Brazier, S.R. Doctrow, C.L. Masters, S.J. Collins, A manganese-superoxide
dismutase/catalase mimetic extends survival in a mouse model of human prion
disease, Free Radic. Biol. Med. 45 (2) (2008) 184–192.
[32] T. Canello, Y. Friedman-Levi, M. Mizrahi, O. Binyamin, E. Cohen, K. Frid,
R. Gabizon, Copper is toxic to PrP-ablated mice and exacerbates disease in a mouse
model of E200K genetic prion disease, Neurobiol. Dis. 45 (3) (2012) 1010–1017.
[33] A.K. Tripathi, S. Haldar, J. Qian, A. Beserra, S. Suda, A. Singh, U. Hopfer, S.
G. Chen, M.D. Garrick, J.R. Turner, M.D. Knutson, N. Singh, Prion protein functions
as a ferrireductase partner for ZIP14 and DMT1, Free Radic. Biol. Med. 84 (2015)
322–330.
[34] D.J. Hare, A. Grubman, T.M. Ryan, A. Lothian, J.R. Liddell, R. Grimm, T. Matsuda,
P.A. Doble, R.A. Cherny, A.I. Bush, A.R. White, C.L. Masters, B.R. Roberts, Profiling
the iron, copper and zinc content in primary neuron and astrocyte cultures by rapid
online quantitative size exclusion chromatography-inductively coupled plasma�mass spectrometry, Metallomics 5 (12) (2013) 1656–1662.
[35] I. Mirabile, P.S. Jat, S. Brandner, J. Collinge, Identification of clinical target areas
in the brainstem of prion-infected mice, Neuropathol. Appl. Neurobiol. 41 (5)
(2015) 613–630.
[36] J.M. Bourgognon, J.R. Steinert, The metabolome identity: basis for discovery of
biomarkers in neurodegeneration, Neural Regen Res 14 (3) (2019) 387–390.
[37] M.H. Yan, X. Wang, X. Zhu, Mitochondrial defects and oxidative stress in
Alzheimer disease and Parkinson disease, Free Radic. Biol. Med. 62 (2013) 90–101.
[38] B.R. Stockwell, J.P. Friedmann Angeli, H. Bayir, A.I. Bush, M. Conrad, S.J. Dixon,
S. Fulda, S. Gascon, S.K. Hatzios, V.E. Kagan, K. Noel, X. Jiang, A. Linkermann, M.
E. Murphy, M. Overholtzer, A. Oyagi, G.C. Pagnussat, J. Park, Q. Ran, C.
S. Rosenfeld, K. Salnikow, D. Tang, F.M. Torti, S.V. Torti, S. Toyokuni, K.
A. Woerpel, D.D. Zhang, Ferroptosis: a regulated cell death Nexus linking
metabolism, Redox Biology, and Disease, Cell 171 (2) (2017) 273–285.
[39] L. Sobrevia, L. Ooi, S. Ryan, J.R. Steinert, Nitric oxide: a regulator of cellular
function in health and disease, Oxid. Med. Cell. Longev. 2016 (2016), 9782346.
[40] J.R. Steinert, T. Chernova, I.D. Forsythe, Nitric oxide signaling in brain function,
dysfunction, and dementia, Neuroscientist 16 (4) (2010) 435–452.
[41] J.R. Wright, Q.F.E. Deen, A. Stevenson, L. Telford-Cooke, C. Parker, C. Martin-Ruiz,
J.R. Steinert, R.N. Kalaria, E.B. Mukaetova-Ladinska, Plasma myeloperoxidase as a
potential biomarker of patient response to anti-dementia treatment in Alzheimer’s
disease, J. Alzheimers Dis. 99 (2022), https://doi.org/10.3233/JAD-220490. In
press.
J.G. Spiers et al.
Free Radical Biology and Medicine 192 (2022) 182–190
190
[42] J.G. Spiers, H.C. Chen, J.M. Bourgognon, J.R. Steinert, Dysregulation of stress
systems and nitric oxide signaling underlies neuronal dysfunction in Alzheimer’s
disease, Free Radic. Biol. Med. 134 (2019) 468–483.
[43] S.M. Rocha, C.M. Bantle, T. Aboellail, D. Chatterjee, R.J. Smeyne, R.B. Tjalkens,
Rotenone induces regionally distinct alpha-synuclein protein aggregation and
activation of glia prior to loss of dopaminergic neurons in C57Bl/6 mice,
Neurobiol. Dis. 167 (2022), 105685.
[44] Y. Nakagawa, S. Yamada, Metal homeostasis disturbances in neurodegenerative
disorders, with special emphasis on Creutzfeldt-Jakob disease - potential
pathogenetic mechanism and therapeutic implications, Pharmacol. Ther. 207
(2020), 107455.
[45] L. Westergard, H.M. Christensen, D.A. Harris, The cellular prion protein (PrP(C)):
its physiological function and role in disease, Biochim. Biophys. Acta 1772 (6)
(2007) 629–644.
[46] S.W. Robinson, M.L. Nugent, D. Dinsdale, J.R. Steinert, Prion protein facilitates
synaptic vesicle release by enhancing release probability, Hum. Mol. Genet. 23 (17)
(2014) 4581–4596.
[47] A.M. Thackray, B. Lam, E.E. McNulty, A.V. Nalls, C.K. Mathiason, S.S. Magadi, W.
S. Jackson, O. Andreoletti, C. Marrero-Winkens, H. Schatzl, R. Bujdoso, Clearance
of Variant Creutzfeldt-Jakob Disease Prions in Vivo by the Hsp70 Disaggregase
System, Brain, 2022.
[48] J.R. Steinert, S. Campesan, P. Richards, C.P. Kyriacou, I.D. Forsythe, F. Giorgini,
Rab11 rescues synaptic dysfunction and behavioural deficits in a Drosophila model
of Huntington’s disease, Hum. Mol. Genet. 21 (13) (2012) 2912–2922.
[49] C. Breda, M.L. Nugent, J.G. Estranero, C.P. Kyriacou, T.F. Outeiro, J.R. Steinert,
F. Giorgini, Rab11 modulates alpha-synuclein-mediated defects in synaptic
transmission and behaviour, Hum. Mol. Genet. 24 (4) (2015) 1077–1091.
[50] H. Vicente Miranda, E.M. Szego, L.M.A. Oliveira, C. Breda, E. Darendelioglu, R.
M. de Oliveira, D.G. Ferreira, M.A. Gomes, R. Rott, M. Oliveira, F. Munari, F.
J. Enguita, T. Simoes, E.F. Rodrigues, M. Heinrich, I.C. Martins, I. Zamolo, O. Riess,
C. Cordeiro, A. Ponces-Freire, H.A. Lashuel, N.C. Santos, L.V. Lopes, W. Xiang, T.
M. Jovin, D. Penque, S. Engelender, M. Zweckstetter, J. Klucken, F. Giorgini,
A. Quintas, T.F. Outeiro, Glycation potentiates alpha-synuclein-associated
neurodegeneration in synucleinopathies, Brain 140 (5) (2017) 1399–1419.
[51] B.R. Roberts, N.K. Lim, E.J. McAllum, P.S. Donnelly, D.J. Hare, P.A. Doble, B.
J. Turner, K.A. Price, S.C. Lim, B.M. Paterson, J.L. Hickey, T.W. Rhoads, J.
R. Williams, K.M. Kanninen, L.W. Hung, J.R. Liddell, A. Grubman, J.F. Monty, R.
M. Llanos, D.R. Kramer, J.F. Mercer, A.I. Bush, C.L. Masters, J.A. Duce, Q.X. Li, J.
S. Beckman, K.J. Barnham, A.R. White, P.J. Crouch, Oral treatment with Cu(II)
(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the
phenotype of a transgenic mouse model of amyotrophic lateral sclerosis,
J. Neurosci. 34 (23) (2014) 8021–8031.
[52] B.R. Stockwell, X. Jiang, The chemistry and biology of ferroptosis, Cell Chem. Biol.
27 (4) (2020) 365–375.
[53] E. Ficiara, Z. Munir, S. Boschi, M.E. Caligiuri, C. Guiot, Alteration of iron
concentration in Alzheimer’s disease as a possible diagnostic biomarker unveiling
ferroptosis, Int. J. Mol. Sci. 22 (9) (2021).
[54] K. Jellinger, W. Paulus, I. Grundke-Iqbal, P. Riederer, M.B. Youdim, Brain iron and
ferritin in Parkinson’s and Alzheimer’s diseases, J. Neural Transm. Park Dis.
Dement Sect 2 (4) (1990) 327–340.
[55] P.W. Mantyh, J.R. Ghilardi, S. Rogers, E. DeMaster, C.J. Allen, E.R. Stimson, J.
E. Maggio, Aluminum, iron, and zinc ions promote aggregation of physiological
concentrations of beta-amyloid peptide, J. Neurochem. 61 (3) (1993) 1171–1174.
[56] J. Becerril-Ortega, K. Bordji, T. Freret, T. Rush, A. Buisson, Iron overload
accelerates neuronal amyloid-beta production and cognitive impairment in
transgenic mice model of Alzheimer’s disease, Neurobiol. Aging 35 (10) (2014)
2288–2301.
[57] H. Jiang, J. Wang, J. Rogers, J. Xie, Brain iron metabolism dysfunction in
Parkinson’s disease, Mol. Neurobiol. 54 (4) (2017) 3078–3101.
[58] E. Oestreicher, G.J. Sengstock, P. Riederer, C.W. Olanow, A.J. Dunn, G.
W. Arendash, Degeneration of nigrostriatal dopaminergic neurons increases iron
within the substantia nigra: a histochemical and neurochemical study, Brain Res.
660 (1) (1994) 8–18.
[59] Y. Zeng, P.S. DiGiacomo, S.J. Madsen, M.M. Zeineh, R. Sinclair, Exploring valence
states of abnormal mineral deposits in biological tissues using correlative
microscopy and spectroscopy techniques: a case study on ferritin and iron deposits
from Alzheimer’s disease patients, Ultramicroscopy 231 (2021), 113254.
[60] S. David, F. Ryan, P. Jhelum, A. Kroner, Ferroptosis in Neurological Disease,
Neuroscientist, 2022, 10738584221100183.
[61] C. Liu, C.W. Zhang, S.Q. Lo, S.T. Ang, K.C.M. Chew, D. Yu, B.H. Chai, B. Tan,
F. Tsang, Y.K. Tai, B.W.Q. Tan, M.C. Liang, H.T. Tan, J.Y. Tang, M.K.P. Lai, J.J.
E. Chua, M.C.M. Chung, S. Khanna, K.L. Lim, T.W. Soong, S-nitrosylation of
divalent metal transporter 1 enhances iron uptake to mediate loss of dopaminergic
neurons and motoric deficit, J. Neurosci. 38 (39) (2018) 8364–8377.
[62] M. Ventriglia, G.J. Brewer, I. Simonelli, S. Mariani, M. Siotto, S. Bucossi, R. Squitti,
Zinc in Alzheimer’s disease: a meta-analysis of serum, plasma, and cerebrospinal
fluid studies, J. Alzheimers Dis. 46 (1) (2015) 75–87.
[63] J.W. Kim, M.S. Byun, D. Yi, J.H. Lee, M.J. Kim, G. Jung, J.Y. Lee, K.M. Kang, C.
H. Sohn, Y.S. Lee, Y.K. Kim, D.Y. Lee, K.R. Group, Serum zinc levels and in vivo
beta-amyloid deposition in the human brain, Alzheimer’s Res. Ther. 13 (1) (2021)
190.
[64] M.P. Cuajungco, G.J. Lees, Nitric oxide generators produce accumulation of
chelatable zinc in hippocampal neuronal perikarya, Brain Res. 799 (1) (1998)
118–129.
[65] D.H. Gou, T.T. Huang, W. Li, X.D. Gao, C. Haikal, X.H. Wang, D.Y. Song, X. Liang,
L. Zhu, Y. Tang, C. Ding, J.Y. Li, Inhibition of copper transporter 1 prevents alpha�synuclein pathology and alleviates nigrostriatal degeneration in AAV-based mouse
model of Parkinson’s disease, Redox Biol. 38 (2021), 101795.
[66] J. Wang, L. Tang, A. Xu, S. Zhang, H. Jiang, P. Pei, H. Li, T. Lv, Y. Yang, N. Qian,
K. Naidu, W. Yang, Identification of mutations in the ATP7B gene in 14 Wilson
disease children: case series, Medicine (Baltim.) 100 (16) (2021), e25463.
[67] N. Bakkar, A. Starr, B.E. Rabichow, I. Lorenzini, Z.T. McEachin, R. Kraft,
M. Chaung, S. Macklin-Isquierdo, T. Wingfield, B. Carhart, N. Zahler, W.H. Chang,
G.J. Bassell, A. Betourne, N. Boulis, S.V. Alworth, J.K. Ichida, P.R. August, D.
C. Zarnescu, R. Sattler, R. Bowser, The M1311V variant of ATP7A is associated
with impaired trafficking and copper homeostasis in models of motor neuron
disease, Neurobiol. Dis. 149 (2021), 10522
References
References